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Pyrazinamide (PZA) is included in the 2016 World Health Organization multidrug-resistant
tuberculosis treatment guidelines and is a key component of most ongoing clinical trials
investigating novel antibiotic combinations. PZA resistance is associated with worse
tuberculosis treatment outcomes. Unfortunately, for such an important drug, phenotypic
susceptibility testing is extremely challenging. The exacting bacterial growth conditions
required to induce susceptibility to the drug reduce the accuracy of the susceptibility assay,
even in experienced laboratories, andwidespread testing is not performed. This situation is
unacceptable for such a valuable and important drug. A more complete understanding
of the mechanism of action of PZA would be expected to lead to improvements in this
situation.
Although the exact mechanism of action of PZA is not known yet, it is widely accepted
that PZA is a prodrug requiring transformation to pyrazinoic acid, the active form, by the
mycobacterial enzyme encoded by the pncA gene. Most clinical resistance indeed appears
to be a result of a diverse range of mutations in this gene and sequencing of the pncA gene
has been shown to have excellent predictive power for PZA resistance. The wider availably
of pncA sequencing in combination with databases of the phenotypic implications of these
mutations has helped make genetic testing for PZA resistance a practical proposition.
For the past decades, it has been generally accepted that an extracellular low pH is
required for PZA activity but work in our laboratory [1] and others [2] has recently chal-
lenged this assumption. Alternative bacterial stresses, apart from a reduced pH of the
growth media (such as reduced temperature), can also induce a PZA-susceptible pheno-
type. The characterization of spontaneous in vitro-resistant pyrazinoic acid mutants
selected under neutral pH conditions suggests a key role for the pantothenate/coenzymeFebruary
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PZA as well as potentially the bacterial population against which PZA is active in the host.
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